BACKGROUND AND AIMS: Many aspects of microscopic colitis remain poorly understood. Our aim was to report a single centre experience with this condition. METHODS: Two hundred and twenty-two patients (52 male, 170 female; median age 64 years; range 32-90) diagnosed between 1993 and 2010 were studied. Medical notes were reviewed, and data on age, gender, clinical features, history of autoimmune diseases, medication use, cigarette smoking, histology and outcome were collected. RESULTS: There were 99 cases of lymphocytic and 123 of collagenous colitis. Diarrhoea was almost invariably present (98 %) while abdominal pain (24 %), weight loss (10 %), faecal incontinence (8 %) and blood PR (5 %) were also described. Twenty-eight percent had concomitant autoimmune diseases, most commonly coeliac disease. Patients were taking a variety of medications at diagnosis thought to be associated with microscopic colitis including NSAIDs (22 %), aspirin (19 %), statins (15 %), proton pump inhibitors (19 %) and SSRIs (10 %) at diagnosis. Prior to the widespread use of budesonide in our institution, 33 % of patients required two or more medications during therapy compared to 15 % following the introduction of budesonide (p = 0.001). Thirty-eight percent of patients achieved spontaneous remission with either no treatment or simple anti-diarrhoeals. Using a multivariate model, the only factor associated with spontaneous remission was male gender (RR 1.9; 95 % CI 1.0-3.6; p = 0.04). Two patients had refractory microscopic colitis; one required a colectomy while a more recent case has responded to anti-TNFα therapy. CONCLUSION: Microscopic colitis is predominantly a benign and self-limiting disorder. The introduction of budesonide has revolutionised treatment of this lesser studied inflammatory bowel disease.
BACKGROUND AND AIMS: Many aspects of microscopic colitis remain poorly understood. Our aim was to report a single centre experience with this condition. METHODS: Two hundred and twenty-two patients (52 male, 170 female; median age 64 years; range 32-90) diagnosed between 1993 and 2010 were studied. Medical notes were reviewed, and data on age, gender, clinical features, history of autoimmune diseases, medication use, cigarette smoking, histology and outcome were collected. RESULTS: There were 99 cases of lymphocytic and 123 of collagenous colitis. Diarrhoea was almost invariably present (98 %) while abdominal pain (24 %), weight loss (10 %), faecal incontinence (8 %) and blood PR (5 %) were also described. Twenty-eight percent had concomitant autoimmune diseases, most commonly coeliac disease. Patients were taking a variety of medications at diagnosis thought to be associated with microscopic colitis including NSAIDs (22 %), aspirin (19 %), statins (15 %), proton pump inhibitors (19 %) and SSRIs (10 %) at diagnosis. Prior to the widespread use of budesonide in our institution, 33 % of patients required two or more medications during therapy compared to 15 % following the introduction of budesonide (p = 0.001). Thirty-eight percent of patients achieved spontaneous remission with either no treatment or simple anti-diarrhoeals. Using a multivariate model, the only factor associated with spontaneous remission was male gender (RR 1.9; 95 % CI 1.0-3.6; p = 0.04). Two patients had refractory microscopic colitis; one required a colectomy while a more recent case has responded to anti-TNFα therapy. CONCLUSION: Microscopic colitis is predominantly a benign and self-limiting disorder. The introduction of budesonide has revolutionised treatment of this lesser studied inflammatory bowel disease.
Authors: Fernando Fernández-Bañares; Monia R de Sousa; Antonio Salas; Belén Beltrán; Marta Piqueras; Eva Iglesias; Javier P Gisbert; Beatriz Lobo; Valentí Puig-Diví; Esther García-Planella; Ingrid Ordás; Montserrat Andreu; Marta Calvo; Miguel Montoro; Maria Esteve; Josep M Viver Journal: Inflamm Bowel Dis Date: 2013-02 Impact factor: 5.325
Authors: Nicole M Gentile; Adil A Abdalla; Sahil Khanna; Thomas C Smyrk; William J Tremaine; William A Faubion; Patricia P Kammer; William J Sandborn; Edward V Loftus; Darrell S Pardi Journal: Am J Gastroenterol Date: 2013-01-08 Impact factor: 10.864
Authors: Darrell S Pardi; Venktesh R Ramnath; Edward V Loftus; William J Tremaine; William J Sandborn Journal: Am J Gastroenterol Date: 2002-11 Impact factor: 10.864
Authors: Ghazaleh Aram; Theodore M Bayless; Zong-Ming Chen; Elizabeth A Montgomery; Mark Donowitz; Francis M Giardiello Journal: Clin Gastroenterol Hepatol Date: 2009-12-28 Impact factor: 11.382
Authors: Kristin E Burke; Ashwin N Ananthakrishnan; Paul Lochhead; Po-Hong Liu; Ola Olen; Jonas F Ludvigsson; James M Richter; Shelley S Tworoger; Andrew T Chan; Hamed Khalili Journal: Gastroenterology Date: 2018-08-23 Impact factor: 22.682
Authors: Kristin E Burke; Ashwin N Ananthakrishnan; Paul Lochhead; Ola Olen; Jonas F Ludvigsson; James M Richter; Andrew T Chan; Hamed Khalili Journal: J Crohns Colitis Date: 2018-04-27 Impact factor: 9.071
Authors: Stephan Miehlke; Danila Guagnozzi; Yamile Zabana; Gian E Tontini; Anne-Marie Kanstrup Fiehn; Signe Wildt; Johan Bohr; Ole Bonderup; Gerd Bouma; Mauro D'Amato; Peter J Heiberg Engel; Fernando Fernandez-Banares; Gilles Macaigne; Henrik Hjortswang; Elisabeth Hultgren-Hörnquist; Anastasios Koulaouzidis; Jouzas Kupcinskas; Stefania Landolfi; Giovanni Latella; Alfredo Lucendo; Ivan Lyutakov; Ahmed Madisch; Fernando Magro; Wojciech Marlicz; Emese Mihaly; Lars K Munck; Ann-Elisabeth Ostvik; Árpád V Patai; Plamen Penchev; Karolina Skonieczna-Żydecka; Bas Verhaegh; Andreas Münch Journal: United European Gastroenterol J Date: 2021-02-22 Impact factor: 4.623